Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 7

1.

A novel combination of withaferin A and sorafenib shows synergistic efficacy against both papillary and anaplastic thyroid cancers.

Cohen SM, Mukerji R, Timmermann BN, Samadi AK, Cohen MS.

Am J Surg. 2012 Dec;204(6):895-900; discussion 900-1. doi: 10.1016/j.amjsurg.2012.07.027.

PMID:
23231932
2.

Sorafenib: a review of its use in advanced hepatocellular carcinoma.

Keating GM, Santoro A.

Drugs. 2009;69(2):223-40. doi: 10.2165/00003495-200969020-00006. Review.

PMID:
19228077
3.

In vitro and in vivo antitumor efficacy of docetaxel and sorafenib combination in human pancreatic cancer cells.

Ulivi P, Arienti C, Zoli W, Scarsella M, Carloni S, Fabbri F, Tesei A, Chiadini E, Orlandi A, Passeri D, Zupi G, Milandri C, Silvestrini R, Amadori D, Leonetti C.

Curr Cancer Drug Targets. 2010 Sep;10(6):600-10. Review.

PMID:
20491617
4.
5.

Withaferin-A--A Natural Anticancer Agent with Pleitropic Mechanisms of Action.

Lee IC, Choi BY.

Int J Mol Sci. 2016 Mar 4;17(3):290. doi: 10.3390/ijms17030290. Review.

6.

A review of molecular mechanisms of the anti-leukemic effects of phenolic compounds in honey.

Abubakar MB, Abdullah WZ, Sulaiman SA, Suen AB.

Int J Mol Sci. 2012 Nov 15;13(11):15054-73. doi: 10.3390/ijms131115054. Review.

7.

Anticancer effects of lactoferrin: underlying mechanisms and future trends in cancer therapy.

Zhang Y, Lima CF, Rodrigues LR.

Nutr Rev. 2014 Dec;72(12):763-73. doi: 10.1111/nure.12155. Review.

PMID:
25406879
Items per page

Supplemental Content

Support Center